ZANETTO, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.097
AS - Asia 851
EU - Europa 818
AF - Africa 10
SA - Sud America 7
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
Totale 6.789
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.085
CN - Cina 374
SG - Singapore 342
IT - Italia 340
FI - Finlandia 106
DE - Germania 79
SE - Svezia 73
GB - Regno Unito 72
FR - Francia 70
VN - Vietnam 55
IN - India 42
IE - Irlanda 18
ES - Italia 12
NL - Olanda 10
TW - Taiwan 9
UA - Ucraina 9
IQ - Iraq 8
JP - Giappone 8
EG - Egitto 7
PL - Polonia 7
RO - Romania 7
CA - Canada 6
HK - Hong Kong 6
CH - Svizzera 5
MX - Messico 5
A2 - ???statistics.table.value.countryCode.A2??? 3
BR - Brasile 3
AT - Austria 2
AU - Australia 2
BE - Belgio 2
CO - Colombia 2
ET - Etiopia 2
GR - Grecia 2
TR - Turchia 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BO - Bolivia 1
DK - Danimarca 1
HU - Ungheria 1
IL - Israele 1
IR - Iran 1
MA - Marocco 1
MT - Malta 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
PR - Porto Rico 1
RS - Serbia 1
SA - Arabia Saudita 1
Totale 6.789
Salva come PNG Salva come JPEG
Città #
Fairfield 946
Woodbridge 473
Houston 406
Ashburn 402
Chandler 395
Cambridge 323
Ann Arbor 306
Seattle 296
Wilmington 264
Singapore 257
San Diego 140
Beijing 106
Medford 104
Princeton 104
Padova 98
Des Moines 79
Helsinki 68
Roxbury 62
Dong Ket 50
Santa Clara 48
Boardman 36
Nanjing 34
Guangzhou 30
Milan 26
London 22
Rome 22
Los Angeles 21
Pune 21
Shanghai 19
Dublin 18
New York 16
Shenyang 14
Phoenix 13
Jinan 11
Kilburn 11
Lappeenranta 10
Nanchang 10
Hebei 9
Taipei 9
Baghdad 8
Vicenza 8
Chiswick 7
Dearborn 7
Tianjin 7
Zhengzhou 7
Hefei 6
Ogden 6
Washington 6
Esslingen am Neckar 5
Florence 5
Kharkiv 5
Munich 5
Ningbo 5
Trieste 5
Udine 5
Warsaw 5
Amsterdam 4
Bologna 4
Changsha 4
Fuzhou 4
Jiaxing 4
Kunming 4
Naples 4
Nonantola 4
Norwalk 4
Redwood City 4
Venice 4
Verona 4
Acton 3
Busto Arsizio 3
De Zilk 3
Detroit 3
Ferrara 3
Frankfurt am Main 3
Genoa 3
Legnaro 3
Lozzo Atestino 3
Málaga 3
Palermo 3
Rizhao 3
Selvazzano Dentro 3
Southwark 3
Tappahannock 3
Tivoli 3
Toluca 3
Vinh 3
Wandsworth 3
Addis Ababa 2
Adligenswil 2
Ahmedabad 2
Anyang 2
Barcelona 2
Borås 2
Boston 2
Brooklyn 2
Brussels 2
Busiago 2
Central 2
Chiari 2
Chicago 2
Totale 5.512
Salva come PNG Salva come JPEG
Nome #
Hepatitis C virus eradication with direct acting antiviral improves insulin resistance 135
Changes in plasma circulating microvesicles in patients with HCV‐related cirrhosis after treatment with direct‐acting antivirals 126
Drop-out rate from the liver transplant waiting list due to HCC progression in HCV-infected patients treated with direct acting antivirals. 118
Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis 117
New Perspectives on Treatment of Hepatitis B Before and After Liver Transplantation 116
Short-term outcomes of pediatric liver transplant recipients after transition to Adult Healthcare Service 113
"DAA in patients with Hepatocellular carcinoma before Liver Transplantation: are we sure is still an open issue?" 111
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study 110
Non-invasive risk stratification after HCV-eradication in patients with advanced chronic liver disease 108
Markers of acute rejection and graft acceptance in liver transplantation. 106
Hepatitis C virus infection in end stage renal disease and kidney transplantation 105
Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study 104
Management of bacterial infection in the liver transplant candidate 103
Acute alcoholic hepatitis and liver transplantation: Waiting for Godot 97
Eradication of HCV in patients awaiting liver transplantation does not increase drop-out due to HCC progression 97
Hypercoagulability In Cirrhotic Patients With Hepatocellular Carcinoma (hcc) and Portal Vein Thrombosis (pvt) 97
Current challenges and future directions for liver transplantation 96
HCC criteria for liver transplantation: Controversies 95
Filling the gap between clinical trials and real life in the treatment of severe HCV recurrence after liver transplantation 94
Orthotopic Liver Transplantation in Alcoholic Liver Disease Patients 94
Recent advances in understanding and managing liver transplantation 93
Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct acting antivirals 91
Hypercoagulability in cirrhotic patients with hepatocellular carcinoma (HCC) and portal vein thrombosis (PVT) 90
PREVALENCE AND RISK FACTORS OF METABOLIC SYNDROME AFTER LIVER TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE 87
HCV eradication is not associated with drop-out due to HCC progression in patients awaiting liver transplantation: A monocentric experience 87
Hemodynamic Evaluation of Nonselective β-Blockers in Patients with Cirrhosis and Refractory Ascites 87
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis 87
Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents 86
Therapeutic approaches for portal biliopathy: A systematic review 85
Drop-out rate due to HCC progression is not affected by HCV eradication with DAAs in patients awaiting liver transplantation 85
Timing for treatment of HCV recurrence after liver transplantation: the earlier the better. 84
Acute Kidney Injury in Decompensated Cirrhosis Is Associated With Both Hypo-coagulable and Hyper-coagulable Features 84
Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma 82
Organ Preservation in Liver Transplantation 82
Liver transplantation for viral hepatitis in 2015 81
Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study 80
Endothelial damage of the portal vein is associated with Heparin-like effect in advanced stages of cirrhosis 80
Hypercoagulability in cirrhotic patients with hepatocellular carcinoma (HCC) and portal vein thrombosis (PVT) 79
Levels of angiogenic proteins in plasma and platelets are not different between patients with hepatitis B/C-related cirrhosis and patients with cirrhosis and hepatocellular carcinoma 79
Mortality in liver transplant recipients with portal vein thrombosis - an updated meta-analysis 79
Hepatitis C virus and liver transplantation: Where do we stand? 78
Acute kidney injury is associated with increased levels of circulating microvesicles in patients with decompensated cirrhosis 77
Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. 76
Local prothrombotic state in portal venous system in cirrhosis 73
No evidence for increased platelet activation in patients with hepatitis B- or C-related cirrhosis and hepatocellular carcinoma 71
Prevalence and risk factors of metabolic syndrome after liver transplantation: a single centre experience 71
Influence of donor and recipient gender on liver transplantation outcomes in Europe 70
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 67
PERIPHERAL NK CELLS IN PATIENTS WITH HCV RECURRENCE AFTER LIVER TRANSPLANTATION DURING INTERFERON-FREE ANTIVIRAL THERAPY 66
Liver Transplantation for Alcoholic Liver Disease and Hepatocellular Carcinoma 64
Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension 62
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study (PLoS ONE (2017) 12: 2 (e0172159) DOI: 10.1371/journal.pone.0172159) 62
Extending transplantation criteria for hepatocellular carcinoma 62
Hepatocellular carcinoma and the risk of de novo malignancies after liver transplantation - a multicenter cohort study 61
EFFECTS OF NON-SELECTIVE beta-BLOCKERS ON HEMODYNAMICS AFTER LARGE VOLUME PARACENTESIS IN PATIENTS WITH CIRRHOSIS LISTED FOR LIVER TRANSPLANTATION: A PRELIMINARY REPORT 57
Determinants of increased thrombotic tendency in NASH cirrhosis: not there yet! 57
Management of portal hypertension severe complications 56
Long-term care of transplant recipients: de novo neoplasms after liver transplantation 53
Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure 51
Hepatocellular carcinoma risk in patients with HBV-related liver disease receiving antiviral therapy 51
Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma 51
Drug induced liver injury: from pathogenesis to liver transplantation 50
The Role of N-Acetylcisteine, Protecting the Graft from the Fibrosis Progression Due To HCV Recurrence, after Liver Transplantation. Long Terms Results of a Randomized Controlled Study. 48
Effects of Non-Selective beta-Blockers on Hemodynamics and Paracentesis Induced Circulatory Dysfunction in Patients with Cirrhosis Undergoing Large Volume Paracentesis: a Preliminary Report 44
Role of local endothelial alterations in the pathogenesis of portal vein thrombosis in cirrhosis 43
CIRCULATING MICROPARTICLES AND RISK OF PORTAL VEIN THROMBOSIS IN PATIENTS WITH LIVER CIRRHOSIS AND HEPATOCELLULAR CARCINOMA 43
Enhanced recovery for liver transplantation: recommendations from the 2022 International Liver Transplantation Society consensus conference 42
Effect of Portal Vein Thrombosis (pvt) On Survival After Liver Transplantation (lt): A Metanalysis 40
ERS Statement on Benign Pleural Effusions in Adults 38
Reply 38
Influence of hepatocellular carcinoma on platelet aggregation in cirrhosis 38
More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC 38
Reduced Clot Stability by Thromboelastography as a Potential Indicator of Procedure-Related Bleeding in Decompensated Cirrhosis 37
Role of non-neoplastic portal vein thrombosis in the natural history of patients with cirrhosis and first diagnosis of hepatocellular carcinoma 36
An Essential Guide for Managing Post-Liver Transplant Patients: What Primary Care Physicians Should Know 36
Sarcopenia in chronic advanced liver diseases: A sex-oriented analysis of the literature 36
Whole blood coagulation tests are not equally able to detect haemostatic prothrombotic alterations in patients with liver cirrhosis and hepatocellular carcinoma (HCC): rotational thromboelastometry versus thrombingeneration test 35
Malnourished cirrhotic patient: what should we do? 35
Hepatitis B and liver transplantation 34
Hepatic benefits of HCV cure: Don't forget coagulation! 34
Comparison of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Portal Vein Thrombosis in Cirrhosis 34
Hepatocellular carcinoma in chronic viral hepatitis: Where do we stand? 34
Reply to "Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis" 34
Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections 33
Milestones in the discovery of Budd-Chiari syndrome 30
Liver Transplantation for NAFLD: indications and post-transplant management 29
SPONTANEOUS BACTERIAL PERITONITIS (SBP) IS NOT ASSOCIATED WITH HIGHER MORTALITY IF COMPARED WITH OTHER INFECTIONS IN PATIENTS AWAITING LIVER TRANSPLANTATION (LT) 29
Circulating microparticles in cirrhotic patients with hepatocellular carcinoma (HCC) and portal vein thrombosis 29
CIRCULATING MICROPARTICLES AND RISK OF PORTAL VEIN THROMBOSIS IN PATIENTS WITH LIVER CIRRHOSIS AND HEPATOCELLULAR CARCINOMA 29
New indications for liver transplantation 29
Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death 25
Long-Term Impact of Direct-Acting Antivirals on Liver Fibrosis and Survival in HCV-Infected Liver Transplant Recipients 24
Changings and Challenges in Liver Transplantation for Nonalcoholic Fatty Liver Disease/Steatohepatitis 23
Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications 22
Circulating microparticles in cirrhotic patients with hepatocellular carcinoma (HCC) and portal vein thrombosis 21
Letter to the editor: Is PAI-1 a thrombotic biomarker in NASH cirrhosis? 21
WHOLE BLOOD COAGULATION TESTS ARE NOT EQUALLY ABLE TO DETECT HAEMOSTATIC PROTHROMBOTIC ALTERATIONS IN PATIENTS WITH LIVER CIRRHOSIS AND HEPATOCELLULAR CARCINOMA: ROTATIONAL THROMBOELASTOMETRY VERSUS THROMBINGENERATION TEST 20
Some Answers and More Questions About Portal Vein Thrombosis in Patients With Decompensated Cirrhosis 20
Decreased hypercoagulable state in hepatitis C virus-cirrhotic patients treated with DAA: the outcome revolution 19
Recent advances in the management of acute variceal hemorrhage 19
Totale 6.435
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.751
article - articoli 34.672
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.423
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020888 0 0 0 60 169 90 121 125 127 86 79 31
2020/2021932 44 38 90 112 28 48 52 66 111 86 88 169
2021/20221.471 64 126 129 98 39 167 129 123 60 81 122 333
2022/2023941 196 80 36 72 159 102 26 59 108 5 80 18
2023/2024903 61 102 92 77 60 96 92 36 40 62 90 95
2024/2025587 11 272 176 128 0 0 0 0 0 0 0 0
Totale 7.004